Sartorius Acquires Novasep’s Chromatography Equipment Division

Sartorius Stedim Biotech has announced, in a Feb. 8, 2022 press release, that it has completed the acquisition of the chromatography equipment division of Novasep, further to the obtainment of the relevant regulatory approvals.

Through the acquisition (the transaction of which was already agreed upon at the beginning of 2021), Sartorius will gain chromatography systems that are primarily suited to smaller biomolecules, such as oligonucleotides, peptides, and insulin, as well as innovative systems for the continuous manufacturing of biologics. Additionally, Sartorius and Novasep have been collaborating since 2018 on the development of an optimized membrane-based, low-pressure chromatography system that productively processes larger molecules.

“This achievement strengthens our relationship with the Sartorius team and represents a great opportunity for the chromatography equipment business to fully deliver its potential and accelerate its growth under this new ownership,” said Michel Spagnol, president & CEO of Novasep, in the press release. “Furthermore, this announcement is aligned with Novasep’s current strategy, which is to prioritize its core business on API [contract development and manufacturing organization] services for the pharmaceutical market.”